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Endometrial cancer (EC) is among the most common gynecological cancers affecting
women worldwide. Despite the early detection and rather high overall survival rate,
around 20% of the cases recur with poor prognosis. The Next Generation Sequencing
(NGS) technology, also known as massively parallel sequencing, symbolizes a high-
throughput, fast, sensitive and accurate way to study the molecular landscape of a
cancer and this has indeed revolutionized endometrial cancer research. Understanding
the potential, advantages, and limitations of NGS will be crucial for the healthcare
providers and scientists in providing the genome-driven care in this era of precision
medicine and pharmacogenomics. This mini review aimed to compile and critically
summarize the recent findings contributed by NGS technology pertaining to EC.
Importantly, we also discussed the potential of this technology for fundamental discovery
research, individualized therapy, screening of at-risk individual and early diagnosis.
Keywords: next generation sequencing, endometrial cancer, molecular landscape, precision medicine, screening,
early diagnosis
OVERVIEW OF ENDOMETRIAL CANCER
Endometrial cancer (EC) ranks as the sixth most frequent cancers among women worldwide with
around 320, 000 reported cases and 76, 000 deaths (International Agency for Research on Cancer
[Iarc], 2014). This cancer is normally detected early with a relatively high overall survival rate (Sgo
Clinical Practice Endometrial Cancer Working Group et al., 2014). However, nearly one fifth of the
cases have poor prognosis with a median survival of about 1 year (Obel et al., 2006; Salvesen et al.,
2012). Unopposed estrogen therapy, estrogen producing tumors, tamoxifen, obesity, nulliparity,
diabetes mellitus, and early onset of menstruation are among the risk factors associated with EC
(Brinton et al., 2005).
Bokhman (1983) was the first to propose the pathogenetic dualistic model of two different
types of endometrial carcinoma, named as type I and type II. Type I endometrioid endometrial
cancer (EEC) is driven by estrogen and represents most of sporadic cases (Bansal et al., 2009).
EEC typically occurs in premenopausal and younger postmenopausal women who often diagnosed
with low-grade well-differentiated tumor thus carrying a better prognosis (Soliman et al., 2005;
Garg and Soslow, 2014). On the contrary, the type II non-endometrioid endometrial carcinoma
(NEEC) accounts for only 10–20% of sporadic endometrial carcinoma with no underlying estrogen
exposure (Doll et al., 2008). NEEC is commonly diagnosed in older postmenopausal women, who
typically present with advanced-stage disease and poor prognosis (Amant et al., 2005). It is also
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associated with high mortality and reduced survival rates
(Hamilton et al., 2006; Mendivil et al., 2009). This classification
is imperfect as the minority of EC characteristic of both groups
may overlap because of heterogeneity of this disease, especially
the high grade EEC (Murali et al., 2014). Characterization of
molecular landscapes will give insights into tumor classification,
which may influence treatment recommendations and provides
prospects for precision medicine. Therefore, there is a need to
explore the molecular landscape of EC treatment using the next
generation sequencing (NGS) approaches.
Lynch Syndrome (LS) is a hereditary cancer syndrome caused
by germline alterations in the DNA mismatch repair (MMR)
genes (Tafe et al., 2014). Those with LS will have an increased
risk of colon cancer. Despite being overlooked in association
with LS, individuals with this syndrome also has 20–60% risk of
developing EC (Tafe et al., 2014). The mutation frequencies of
MMR genes are: 50–66% in MSH2, 24–40% in MLH1, 10–13% in
MSH6 and<5% in PMS2 (Wang et al., 2013).
OVERVIEW OF NEXT GENERATION
SEQUENCING (NGS) TECHNOLOGY
The emergence of NGS three decades after Sanger sequencing
represents the potential to dramatically revolutionize biomedical
research by enabling the high throughput comprehensive
analysis of genomes and transcriptomes at an inexpensive scale
(Shendure and Ji, 2008). Compared with Sanger sequencing,
NGS technologies offer extraordinarily high throughput capacity
which reduces cost per base, time and has enabled the discovery
of both common and rare variants with a much deeper
sequencing read coverage (Koboldt et al., 2013). NGS is also a
versatile technology which enables various applications including
whole genome sequencing (WGS) for model and non-model
organisms (Ng and Kirkness, 2010), whole exome sequencing
(Rabbani et al., 2014), targeted resequencing (Meldrum et al.,
2011) as well as analysis of coding and non-coding RNA
expression, alternative splicing and discovery of novel non-
coding RNAs (Wang et al., 2009). In addition, while 30× coverage
for WGS is considered as the standard (Rehm et al., 2013),
low-pass WGS with coverage less than 10× had also been used
to assess structural variation (Cancer Genome Atlas Research
Network et al., 2013).
Over the past 4 years, NGS technologies were applied in
EC research (Table 1). NGS has promoted and improved the
detection of key types of molecular alterations such as single
nucleotide substitutions, small insertions, and deletions, copy
number alterations, structural variations and novel transcripts.
New drug targets were identified thus providing the oncologists
with various potential options in treating EC patients (Figure 1).
Here, we provide an overview of the use of NGS for subtype
classification, identification of potential diagnostic biomarkers
and screening of therapeutic targets for personalized treatment
of EC.
Whole genome sequencing provides a comprehensive view of
the cancer genome including all types of somatic/germline
mutations, nucleotide substitutions, small insertions
and deletions, copy number variations, chromosomal
rearrangements, as well as analysis of the non-coding
regions (Meyerson et al., 2010). Since WGS is still expensive,
laborious and produces a massive amount of data for analysis
and interpretation, whole exome sequencing (WES) which
concentrates only on the protein-coding exon of human genome
is a preferred alternative (Rabbani et al., 2014).
However, despite being high throughput, most of the
information obtained from WGS and WES are functionally
unclear and the genetic alterations could be just possible
passenger mutations with unknown clinical significance
(Meldrum et al., 2011). Besides, WGS and WES are unsuitable
for clinical application because of relatively lower read depth
and this later limit the identification of low-allelic-fraction
single nucleotide polymorphisms (SNPs) which is important for
early diagnosis, prevention of drug resistance and residual tumor
detection (Xu et al., 2014). Therefore, deep sequencing of targeted
gene provides better alternative in clinical setting due to several
advantages including higher coverage for increased analytical
sensitivity and specificity, generate feasible and interpretable
data, significant cost reduction, and shorter turnaround time
(Xu et al., 2014). Targeted gene sequencing also has proven
useful for a large number of applications including studying
disease-relevant gene subsets, diagnostic testing for hereditary
disorders and therapeutic decision-making for somatic cancers
(Rehm, 2013).
Since last decade, EC transcriptomes have been dominantly
investigated using hybridization-based microarray techniques
(Maxwell et al., 2005; Cohn et al., 2010; Ratner et al., 2010). The
advent of NGS has also revolutionized cancer transcriptomics
studies. RNA and miRNA sequencing have rapidly emerged as
powerful tools for genome wide expression profiling and offer
several advantages over conventional microarray.
WHOLE GENOME AND WHOLE EXOME
SEQUENCING
To date, there is only one publication in EC by The Cancer
Genome Atlas (TCGA) group which utilized WGS to characterize
the chromosomal aberration in 106 ECs (Cancer Genome Atlas
Research Network et al., 2013). Recurrent translocations of genes
in important cancer pathways including WNT, EGFR–RAS–
MAPK, PI3K, protein kinase A, retinoblastoma and apoptosis
were identified (Cancer Genome Atlas Research Network et al.,
2013). The most frequent translocations were discovered in
a member of the BCL family which were BCL2, BCL7A,
BCL9, and BCL2L11 (Cancer Genome Atlas Research Network
et al., 2013). This large-scale consortium also performedWES
on 248 ECs and identified novel POLE hotspot mutations
(Pro286Arg and Val411Leu) in 13 of the 17 ultra-mutated
samples (Cancer Genome Atlas Research Network et al., 2013).
In addition, PTEN, PIK3R1, PIK3CA, FBXW7, and KRAS were
found to be significantly mutated. This was the largest genomic
characterization of EC so far and their findings propose a
reclassification that might assist in personalized treatment for
patients with aggressive phenotype.
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TABLE 1 | Main findings contributed by Next Generation Sequencing (NGS) in endometrial cancers (ECs).
Method Samples Main findings Study
Low-pass whole genome
sequencing
ECs and matched DNA from normal
tissues or blood (n = 106 pairs)
Recurrent translocations of genes in WNT,
EGFR–RAS–MAPK, PI(3)K, protein kinase A,
retinoblastoma and apoptosis pathway.
The most frequent translocations in the member of
BCL family (BCL2, BCL7A, BCL9, and BCL2L11).
Cancer Genome Atlas
Research Network et al., 2013
Whole exome sequencing ECs and matched DNA from normal
tissues or blood (n = 248 pairs)
Frequent mutations in PTEN, CTNNB1, PIK3CA,
ARID1A, KRAS and novel mutations in ARID5B.
Significant increase of transversion mutation
frequency and novel hotspot mutations in POLE in
a subset of endometrioid cancers.
Whole exome sequencing EC and matched DNA from blood
(n = 13 pairs)
Mutation on ARID1A are associated with PI3K
pathway activation.
Liang et al., 2012
Whole exome sequencing Uterine serous cancer and matched
normal tissues (n = 13 pairs)
Mutation on chromatin-remodeling and ubiquitin
ligase complex genes.
Le Gallo et al., 2012
Whole exome sequencing Uterine serous cancer and matched
DNA from blood or tissue samples
(n = 10 pairs)
Mutation on FBXW7 and amplification of CCNE1
locus (encodes cyclin E, substrate of FBXW7).
Kuhn et al., 2012
Whole exome sequencing Uterine serous cancer (n = 52) and
matched DNA from blood (n = 34)
Mutation on SPOP, CDH4, TAF1, amplification of
CCNE1 and loss of MBD3.
Zhao et al., 2013
Targeted gene sequencing (nine
genes)
Low-grade EEC (n = 276), grade 3
EEC (n = 30), serous (n = 37) and
carcinosarcoma subtype (n = 42)
Distinct mutation frequency on PTEN and TP53 on
low-grade EEC and grade 3 EEC. Significantly
different mutations frequency on PTEN, ARID1A,
PPP2R1A, TP53, and CTNNB1 between grade 3
EEC and serous carcinoma.
McConechy et al., 2012
Targeted gene sequencing
(seven genes)
EEC (n = 307) and ovarian
endometrioid cancer (n = 33)
Distinct mutation profile in PTEN and CTNNB1. McConechy et al., 2014
Targeted gene sequencing (578
genes)
EC (n = 10) Frequent mutations in PTEN (50%) and genes
involved in the endometrial cancer-related
molecular pathway including IL-7 signaling pathway.
Chang et al., 2016
RNA sequencing ECs (n = 333) Three clusters; mitotic, hormonal and
immunoreactive
Cancer Genome Atlas
Research Network et al., 2013
Small RNA sequencing ECs (n = 367) Six miRNA clusters significantly associated with
MLH1 hypermethylation (miR-148a and miR-375),
histology, grade (miR-21) and stage.
RNA sequencing Stage I EEC and adjacent normal
tissues (n = 3 pairs)
First report on dysregulation of miRNAs
(hsa-miR-196a-5p, hsa-miR-328-3p,
hsa-miR-337-3p, and hsa-miR-99a-3p) in EC.
Xiong et al., 2014
Small RNA sequencing Normal, hyperplastic, and EC biopsies
(n = 10 trios)
Definition of sncRNAs signature (1229 miRNAs, 10
piRNAs and three SnoRNAs) involved in neoplastic
transformation.
Ravo et al., 2015
Paired end RNA sequencing EC with matched non-cancerous tissue
(n = 9 pairs)
Significant upregulation of fusion gene
TSNAX-DISC1 in EC which formed through splicing
without chromosomal rearrangement.
Li et al., 2014
EEC, Endometrial endometrioid carcinoma; sncRNAs, Small non-coding RNAs; miRNAs, MicroRNAs; piRNAs, Piwi-interacting RNA; SnoRNAs, Small nucleolar RNAs.
So far there are four published EC studies utilizing WES
(Table 1). Liang et al. (2012) was the first to perform WES in 13
ECs with matched normal DNA. In combination with functional
genomics, the authors identified 12 potential driver genes
including 10 tumor suppressor genes (ARID1A, INHBA, KMO,
TTLL5, GRM8, IGFBP3, AKTIP, PHKA2, TRPS1, and WNT11)
and two oncogenes (ERBB3 and RPS6KC1). Concentrating on
ARID1A, mutation profiles were integrated with functional
proteomics in additional 222 EC samples, demonstrating the role
of ARID1A as a novel regulator of PI3K pathway activity (Liang
et al., 2012).
While Liang et al. (2012) characterized the exomes of ECs
without stratification of grade and histological subtypes, another
group (Le Gallo et al., 2012) focused on the rare but aggressive
serous carcinoma subtype of EC which has high recurrence
rate, poor survival and more likely to present with metastatic
disease due to resistance to chemotherapy (Hamilton et al., 2006).
Le Gallo et al. (2012) performed WES on 13 matched pairs
of serous ECs and normal tissues. In addition to confirming
the existence of alterations in TP53, PIK3CA and PPP2R1A,
they also identified high frequency of somatic alterations in
novel genes involved in serous ECs which were FBXW7, CHD4,
SPOP, MAP3K4, ABCC9, and CYP4X1 (Le Gallo et al., 2012).
Chromatin remodeling and ubiquitin ligase complex pathways
were found to be the most perturbed pathways which have
been associated with frequent alterations in set of 11 chromatin
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FIGURE 1 | Cellular pathways currently being targeted in the treatment of endometrial cancer (EC) and the potential actionable genes in EC
identified via Next Generation Sequencing (NGS). Red star depicted genes with clinically cancer-relevant drug interactions as defined by DGIdb (Wagner et al.,
2016). (A) PI(3)K, MAPK, p53 and apoptosis pathway involving PIK3CA, PTEN, PPP2R1A, KRAS, P53, and BCL2, (B) cell cycle pathway involving FBXW7 and
CCNE1 as well as (C) DNA replication pathway in eukaryote which involves POLE (DNA polymerase ε). Figures were adapted from Kanehisa et al. (2016) and
Seshagiri (2013). Adapted by permission from Macmillan Publishers Ltd: [NATURE GENETICS] (Seshagiri), copyright (2013).
remodeling genes including CHD4 gene and component of
ubiquitin ligase complex (FBXW7 and SPOP gene), respectively
(Le Gallo et al., 2012).
In the same year, Kuhn et al. (2012) performed WES on 10
uterine serous carcinomas with matched normal blood or tissue
samples. In addition to confirming the previous discovery by Le
Gallo et al. (2012), they also identified high mutation frequencies
of FBXW7 and genes known to be associated with serous EC
including TP53, PIK3CA, and PPP2R1A. DNA copy number
analysis revealed concurrent frequent genomic amplification
of the CCNE1 with FBXW7 mutations, suggesting that these
genes are involved in same signaling pathway (Kuhn et al.,
2012). They also proposed the role of endometrial intraepithelial
carcinoma as a precursor to serous carcinoma whereby nine
cases of serous carcinoma with an associated serous endometrial
intraepithelial carcinoma had concordant PIK3CA, PP2R1A, and
TP53 mutations (Kuhn et al., 2012). Taken together, the authors
presented molecular genetic alterations involving the p53, cyclin
E-FBXW7 and PI3K pathways as the major mechanisms in the
uterine serous carcinoma progression.
The WES findings from both rather underpowered studies
by Kuhn et al. (2012) and Le Gallo et al. (2012) were later
supported by Zhao et al. (2013) using five times more samples.
Fifty two uterine serous cancer patients of which 34 had matched
normal tissue samples were subjected to WES (Zhao et al.,
2013). In addition to earlier published studies which identified
frequent alterations in TP53, PIK3CA, PPPR1A, and FBXW7,
Zhao et al. (2013) also discovered high frequency mutations
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of the SPOP gene which targets the protein for ubiquitination.
Interestingly, this study also reported alterations in TF1 gene, an
element of the core TFIID transcriptional machinery which may
result in overexpression of cyclin D and subsequently promote
cell cycle progression and proliferation (Zhao et al., 2013).
Frequent TP53 deletions and amplifications of chromosome
segments containing PIK3CA and CCNE1 are known to be
targets of FBXW7 (Kuhn et al., 2012). This study also discovered
overexpression of ERBB2 which act as an upstream regulator
of PIK3CA/AKT/mTOR signaling pathway and loss of MBD3
gene function, a member of the NuRD-chromatin-modification
complex (Zhao et al., 2013). To summarize, all of these studies
which employed WGS and WES reported specific pathways
that are frequently mutated in ECs including DNA damage,
chromatin remodeling, cell cycle, and cell proliferation pathways.
TARGETED GENE SEQUENCING
Two different studies by McConechy et al. (2012) took on to
improve the controversial classification among pathological
subtypes endometrial carcinoma (endometrioid, serous,
carcinosarcoma, mixed, and clear cell) and between histological
endometrioid types of EC and ovarian cancer using a panel of
genes related to both cancers. The first study involved targeted
enrichment sequencing on a large cohort of 393 EC samples
using a nine-gene panel: ARID1A, PPP2R1A, PTEN, PIK3CA,
KRAS, CTNNB1, TP53, BRAF and PPP2R5C (McConechy
et al., 2012). Both low-grade and grade 3 endometrioid
EC demonstrated a similar pattern of high frequency of
mutations in PTEN, PIK3CA, ARID1A, KRAS, and CTNNB1
(McConechy et al., 2012). There is a significant increase in
TP53 mutation frequency in grade 3 endometrioid EC when
compared to low-grade EC (McConechy et al., 2012). ARID1A
mutation was significantly associated with concurrent PTEN
and PIK3CA mutations in both low-grade endometrioid EC
and grade 3 endometrioid ECs, suggesting a cooperative role
in endometrioid carcinogenesis (McConechy et al., 2012).
However, this phenomenon was not observed in endometrial
serous carcinomas which have frequent mutations in TP53 and
PPP2R1A but lack mutations in PTEN, ARID1A, and CTNBB1.
On the other hand, in carcinosarcoma, two distinct mutation
profiles have been identified which were the endometrioid type
(PTEN, PIK3CA, ARID1A, and KRAS mutations) and serous
type (TP53 and PPP2R1A; McConechy et al., 2012).
Using a panel of seven well-characterized genes in ECs
(ARID1A, PTEN, PIK3CA, KRAS, CTNNB1, PPP2R1A,
and TP53), McConechy’s research group compared two
morphologically similar cancer types, endometrial endometrioid
carcinoma (n = 307) and ovarian endometrioid carcinoma
(n= 33) using exon capture sequencing (McConechy et al., 2014).
Higher frequency of mutations was discovered in low-grade
endometrial endometrioid carcinoma (67%) compared to low-
grade ovarian endometrioid carcinoma (17%; McConechy et al.,
2014). The frequency of CTNNB1 mutation was significantly
higher in ovarian endometrioid cancer (53%) when compared
to endometrioid EC (28%). However, mutations frequencies
in other genes were not significantly different between both
cancers. They hypothesized that the different mutation spectrum
in both cancers might be because of different exposures to
the microenvironment during carcinogenesis, whereby the
ovarian endometrioid carcinoma thrives in a highly oxidative
environment that promotes tumorigenesis (Kobayashi et al.,
2009). Consistent with other previously discussed studies,
distinct mutation patterns in PI3K and WNT signaling pathways
were identified, suggesting therapeutic opportunities for
treatment of EC (McConechy et al., 2014).
The most recently published endometrial research using NGS
involved 10 Taiwanese EC patients (Chang et al., 2016). The
exomes of 578 cancer-related genes were captured and deep-
sequenced using NGS, resulting in average of 500× coverage.
This study revealed 120 variants in 99 genes, with 50% of
the ECs harboring mutations in the PTEN (Chang et al.,
2016). Molecular aberrations in PIK3R1, AKT2 and FOXO1 that
could led to putative activation of the IL-7 signaling pathway
and which has not been previously linked with EC, are also
reported.
Targeted NGS represents a potential to be adopted in
clinical laboratory practices and have diagnostic applications
for screening of individual at risk for developing EC (Tafe,
2015). To date, there are seven NGS-based assays that
include LS-associated genes offered by several reference
laboratories including Ambry Genetics (ColoNext; 14 genes),
ARUP (Gastrointestinal Hereditary Cancer Panel; 15 genes),
Baylor Miraca Genetics Laboratories (High Risk Hereditary
Colorectal Cancer Panel; 12 genes), GeneDx (OncoGeneDx:
Lynch/Colorectal Cancer High Risk Panel; seven genes), Mayo
Medical laboratories (Hereditary Colon Cancer Multi-Gene
Panel; 17 genes), Myriad (myRiskTM Hereditary Cancer Panel;
25 genes) and University of Washington (ColoSeqTM; 23
genes; Tafe, 2015). However, the important challenges of NGS
include interpreting incidental findings, genetic counseling,
and getting informed consent from the patients. These calls for
development of clinical practice guidelines for test development,
validation, reporting, and reporting of incidental findings (Tafe,
2015).
RNA AND miRNA SEQUENCING
Via RNA sequencing and unsupervised k-means clustering of
333 ECs, Cancer Genome Atlas Research Network et al. (2013)
identified three robust clusters which were mitotic, hormonal and
immunoreactive subtypes. The mitotic subtype was characterized
by TP53 alteration and mostly comprised of serous/mixed
histology and endometrioid grade 3 while both of hormonal
and immunoreactive subtypes were predominantly comprised
of endometrioid grade 1/2 and PTEN mutated patients (Cancer
Genome Atlas Research Network et al., 2013). Interestingly, the
hormonal subtype exhibited upregulation of hormone related
genes (ESR1, PGR and downstream targets) which could make
the patients more responsive to hormonal therapy (Cancer
Genome Atlas Research Network et al., 2013), implying potential
for individualized treatment. In addition, the group performed
Frontiers in Pharmacology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 409
fphar-07-00409 October 27, 2016 Time: 16:44 # 6
Suhaimi et al. NGS in Endometrial Cancer
unsupervised consensus clustering of miRNA expression profiles
in 367 ECs and discovered six clusters which some of them
were significantly associated with MLH1 hypermethylation
(miR-148a and miR-375), histology, grade (miR-21) and
stage.
Xiong et al. (2014) simultaneously characterized the
transcriptome of both mRNAs and miRNAs using RNA
sequencing on three pairs of stage 1 endometrioid EC and
adjacent non-cancerous tissue (Xiong et al., 2014). By integrating
expression data of mRNAs and miRNAs, they identified a total
of 438 target pairs which were inversely correlated including 320
dysregulated genes. Downstream pathway enrichment analysis
revealed six differently expressed miRNAs (hsa-let-7c-5p,
hsa-miR-196a-5p, hsa-miR-328-3p, hsa-miR-337-3p, and hsa-
miR-99a-3p, hsa-miR-181c-3p) targeting 11 differently expressed
genes (E2F5, CDKN2A, CCNA2, TP53, BUB1B, CCNE1, CDK1,
MCM4, SKP2, CDC6 and TGFB3) in the cell cycle pathway
(Xiong et al., 2014).
A genome wide characterization of small non-coding
RNAs (sncRNAs) in EC carcinogenesis was performed on
biopsies of normal (n = 10), hyperplastic (n = 6) and
tumor Type 1 endometrial tissues (n = 10) using RNA
sequencing (Ravo et al., 2015). Significant patterns in sncRNA
expression between the sample groups were identified and
led to the discovery of sncRNAs signature (129 miRNAs, 10
piRNAs, and three snoRNAs) which is said to be involved in
neoplastic transformation (Ravo et al., 2015). Integrated gene
expression profiling with the aberrantly expressed sncRNAs
signature revealed their involvement in multiple signaling
pathway including ERK/MAPK, TGF-β and Wnt/β-catenin
in both hyperplastic and neoplastic tissues (Ravo et al.,
2015).
Gene fusion refers to an aberrant rearrangement between
two genes which encode a new fusion protein, serving as a
strong driver mutation in cancer (Mertens et al., 2015). Through
pair-end RNA sequencing in nine pairs of EC and matched
non-cancerous tissues, a fusion gene called chimeric translin-
associated X-disrupted-in-schizophrenia (TSNAX-DISC1) in EC
was discovered (Li et al., 2014). This fusion transcript was
formed by intragenic splicing and its expression was further
validated in 176 paired ECs and matched non-cancerous tissues.
Dysregulation of TSNAX is presumed to be associated with
cancer and the authors proposed the potential of TSNAX–DISC1
as an EC biomarker (Li et al., 2014).
CONCLUSION
In this mini review, we compiled and concisely review
the literatures using NGS in basic EC research. NGS has
indeed revolutionized EC genomics by enabling discovery of
the major alterations in the genome which could serve as
potential biomarkers for prognosis and drug development.
The discovery of these biomarkers by NGS has the potential
to accelerate application of genome-guided information into
precision medicine and pharmacogenomics. Despite limited
publications so far, NGS assays are already actively adopted for
routine clinical testing in molecular pathology laboratories for
identification of individual at risk of developing EC.
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